Laryngeal Cryotherapy for Refractory Neurogenic Cough
Trial Parameters
Brief Summary
This study aims to evaluate the safety and efficacy of upper aerodigestive tract cryotherapy treatment in patients with refractory neurogenic cough in a prospective pilot study with a validated patient reported outcome measure
Eligibility Criteria
Inclusion Criteria: * Adult patients 18 years or older with diagnosis of neurogenic cough * Neurogenic cough is a diagnosis of exclusion applied to persistent cough (8 weeks or longer) * Negative workup for other causes, including sinonasal allergies/chronic sinusitis, cough-variant asthma, and GERD * Patient willing to participate in a clinical trial Exclusion Criteria: * Uncontrolled reflux (scoring on Reflux Symptom index of 13 or higher) * Vocal fold abnormalities or impairment * History of asthma or other underlying lung condition not adequately treated or controlled * Uncontrolled Allergic Rhinitis (Total Nasal Symptom Score \>6, which would indicate moderate disease32) * Reported symptom of postnasal drip * Current smoker * Current neuromodulator medication use * Patient unwilling to participate in clinical trial or sign an informed consent * End stage medical disease with poor life expectancy * Medical instability deemed by the investigators as a contraindication for enrollment